Acute myeloid leukaemia in adults

The Lancet

Volumn 381, Issue 9865, 2013, Pages 484-495

  Ferrara, Felicetto ^a   Schiffer, Charles A ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BREAKPOINT CLUSTER REGION PROTEIN; CD135 ANTIGEN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE PHOSPHATE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; PROTEIN KAT6A; PROTEIN P53; PROTEIN RBM15; RAS PROTEIN; RETINOIC ACID; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL RESEARCH; CONFERENCE PAPER; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOGENETICS; DRUG MEGADOSE; GENE EXPRESSION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; NEUTROPHIL COUNT; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 84873580363     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61727-9     Document Type: Conference Paper

References (140)

1. CH Pui, RC Ribeiro, ML Hancock et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia N Engl J Med 325 1991 1682 1687
2. RA Larson Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms J Clin Oncol 30 2012 2300 2302
3. AD D'Andrea Targeting DNA repair pathways in AML Best Pract Res Clin Haematol 23 2010 469 473
4. U Bacher, S Schnittger, T Haferlach Molecular genetics in acute myeloid leukemia Curr Opin Oncol 22 2010 646 655
5. G Marcucci, T Haferlach, H Döhner Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications J Clin Oncol 29 2011 475 486
6. DG Gilliland, CT Jordan, CA Felix The molecular basis of leukemia Hematology Am Soc Hematol Educ Program 2004 80 97
7. C Schiffer, RM Stone Acute myeloid leukaemia in adults: mast cell leukaemia and other mast cell neoplasms WK Hong RC Bast WN Hait Holland-Frei Cancer Medicine 8th edn. 2010 PMPH USA Shelton
8. Y Shen, YM Zhu, X Fan et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia Blood 118 2011 5593 5603
9. K Eppert, K Takenaka, ER Lechman et al. Stem cell gene expression programs influence clinical outcome in human leukemia Nat Med 17 2011 1086 1093
10. MJ Walter, D Shen, L Ding et al. Clonal architecture of secondary acute myeloid leukemia N Engl J Med 366 2012 1090 1098
11. L Ding, TJ Ley, DE Larson et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 481 2012 506 510
12. JC Byrd, AS Ruppert, K Mrozek et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461 J Clin Oncol 22 2004 1087 1094
13. CD Bloomfield, AS Ruppert, K Mrozek et al. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461 Ann Hematol 83 suppl 2004 S84 S85
14. ML Slovak, H Gundacker, CD Bloomfield et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies Leukemia 20 2006 1295 1297
15. S Lugthart, E van Drunen, Y van Norden et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated Blood 111 2008 4329 4337
16. M Fang, B Storer, E Estey et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation Blood 118 2011 1404 1490
17. JC Byrd, K Mrozek, RK Dodge et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336
18. D Grimwade, RK Hills, AV Moorman et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Blood 116 2010 354 365
19. ML Slovak, KJ Kopecky, PA Cassileth et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 2000 4075 4083
20. JW Vardiman, J Thiele, DA Arber et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
21. H Dohner, EH Estey, S Amadori et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
22. G Marcucci, K Mrozek, MD Radmacher, R Garzon, CD Bloomfield The prognostic and functional role of microRNAs in acute myeloid leukemia Blood 117 2011 1121 1129
23. H Becker, G Marcucci, K Maharry et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study J Clin Oncol 28 2010 596 604
24. B Falini, MP Martelli, N Bolli et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117 2011 1109 1120
25. A Dufour, F Schneider, KH Metzeler et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome J Clin Oncol 28 2010 570 577
26. BJ Wouters, B Lowenberg, CAWL Erpelinck-Verschueren, PJ Valk, R Delwel Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 113 2009 3088 3091
27. AK Burnett, RK Hills, C Green et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA Blood 115 2010 948 956
28. U Bacher, C Haferlach, W Kern, T Haferlach, S Schnittger Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients Blood 111 2008 2527 2537
29. W Li, L Zhang, L Huang, Y Mi, J Wang Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML Leuk Res 36 2012 186 189
30. P Paschka, G Marcucci, AS Ruppert et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study J Clin Oncol 24 2006 3904 3911
31. JA Pollard, TA Alonzo, RB Gerbing et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML Blood 115 2010 2309 2372
32. O Abdel-Wahab, A Mullally, C Hedvat et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114 2009 144 147
33. WC Chou, SC Chou, CY Liu et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics Blood 118 2011 3803 3810
34. I Fried, C Bodner, MM Pichler et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia Haematologica 97 2012 246 250
35. HA Hou, YY Kuo, CY Liu et al. DNMT3A mutations in acute myeloid leukemia-stability during disease evolution and the clinical implication Blood 119 2012 559 568
36. TJ Ley, L Ding, MJ Walter et al. DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2010 2424 2433
37. CL Green, CM Evans, RK Hills, AK Burnett, DC Linch, RE Gale The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status Blood 116 2010 2779 2782
38. G Marcucci, K Maharry Wu YZ et al IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study J Clin Oncol 28 2010 2348 2355
39. KH Metzeler, H Becker, K Maharry et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category Blood 118 2011 6920 6929
40. M Levis, F Ravandi, ES Wang et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Blood 117 2011 3294 3301
41. M Jongen-Lavrencic, SM Sun, MK Dijkstra, PJ Valk, B Lowenberg MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia Blood 111 2008 5078 5085
42. G Marcucci, K Maharry, MD Radmacher et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study J Clin Oncol 26 2008 5078 5087
43. CD Baldus, C Thiede, S Soucek, CD Bloomfield, E Thiel, G Ehninger BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications J Clin Oncol 24 2006 790 797
44. M Heuser, G Beutel, J Krauter et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics Blood 108 2006 3898 3905
45. G Marcucci, CD Baldus, AS Ruppert et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study J Clin Oncol 23 2005 9234 9242
46. B Falini, C Mecucci, E Tiacci et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 2005 254 266
47. RE Gale, C Green, C Allen et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood 111 2008 2776 2784
48. S Schnittger, C Schoch, M Dugas et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59 66
49. C Thiede, C Steudel, B Mohr et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis Blood 99 2002 4326 4335
50. SP Whitman, KJ Archer, L Feng et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study Cancer Res 61 2001 7233 7239
51. K Dohner, RF Schlenk, M Habdank et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations Blood 106 2005 3740 3746
52. RF Schlenk, K Dohner, J Krauter et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 2008 1909 1918
53. JP Patel, M Gonen, ME Figueroa et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia N Engl J Med 366 2012 1079 1089
54. TJ Ley, ER Mardis, L Ding et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome Nature 456 2008 66 72
55. GJ Roboz, M Guzman Acute myeloid leukemia stem cells: seek and destroy Expert Rev Hematol 2 2009 663 672
56. Y Oki, JP Issa Epigenetic mechanisms in AML - a target for therapy Cancer Treat Res 145 2010 19 40
57. AM Melnick Epigenetics in AML Best Pract Res Clin Haematol 23 2010 463 468
58. B Hackanson, KL Bennett, RM Brena et al. Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia Cancer Res 68 2008 3142 3151
59. F Ferrara, S Palmieri, F Leoni Clinically useful prognostic factors in acute myeloid leukemia Crit Rev Oncol Hematol 66 2008 181 193
60. RB Walter, M Othus, G Borthakur et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment J Clin Oncol 29 2011 4417 4423
61. U Krug, C Röllig, A Koschmieder et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes Lancet 376 2010 2000 2008
62. CA Schiffer, KC Anderson, CL Bennett et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 2001 1519 1538
63. OA Cornely, J Maertens, DJ Winston et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359
64. B Lowenberg, GJ Ossenkoppele, W van Putten et al. High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
65. J Menzin, K Lang, CC Earle, D Kerney, R Mallick The outcomes and costs of acute myeloid leukemia among the elderly Arch Intern Med 162 2002 1597 1603
66. G Juliusson, V Lazarevic, AS Horstedt, O Hagberg, M Hoglund Acute myeloid leukemia in the real world: why population-based registries are needed Blood 119 2012 3890 3899
67. BD Cheson, JM Bennett, KJ Kopecky et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia J Clin Oncol 21 2003 4642 4649
68. F Buccisano, L Maurillo, MI Del Principe et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia Blood 119 2012 332 341
69. JE Rubnitz, H Inaba, G Dahl et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial Lancet Oncol 11 2010 543 552
70. RB Walter, HM Kantarjian, X Huang et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study J Clin Oncol 28 2010 1766 1771
71. JW Yates, HJ Wallace Jr, RR Ellison, JF Holland Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia Cancer Chemother Rep 57 1973 485 488
72. Z Arlin, DC Case Jr, J Moore et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group Leukemia 4 1990 177 183
73. E Berman, G Heller, J Santorsa et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77 1991 1666 1674
74. PH Wiernik, PL Banks, DC Case et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 79 1992 313 319
75. JF Bishop, JP Matthews, GA Young et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia Blood 87 1996 1710 1717
76. GH Lyman, DC Dale, DA Wolff et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review J Clin Oncol 28 2010 2914 2924
77. EH Estey, PF Thall, JE Cortes et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts Blood 98 2001 3575 3583 15
78. FR Appelbaum Haematological cancer: The rule of three in AML induction-is cladribine the answer? Nat Rev Clin Oncol 9 2012 376 377
79. J Holowiecki, S Grosicki, S Giebel et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study J Clin Oncol 30 2012 2441 2448
80. AK Burnett, RK Hills, D Milligan et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
81. S Castaigne, C Pautas, C Terre et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 379 2012 1508 1516
82. AK Burnett, NH Russell, RK Hills et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia J Clin Oncol 30 2012 3924 3943
83. S Knapper The clinical development of FLT3 inhibitors in acute myeloid leukemia Expert Opin Investig Drugs 20 2011 1377 1395
84. T Kindler, DB Lipka, T Fischer FLT3 as a therapeutic target in AML: still challenging after all these years Blood 116 2010 5089 5102
85. HF Fernandez, Z Sun, X Yao et al. Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
86. T Buchner, WE Berdel, C Schoch et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia J Clin Oncol 24 2006 2480 2489
87. F Ferrara, T Izzo, C Criscuolo, C Riccardi, M Celentano, G Mele Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results Am J Hematol 85 2010 687 690
88. JM Rowe Consolidation therapy: what should be the standard of care? Best Pract Res Clin Haematol 21 2008 53 60
89. RJ Mayer, RB Davis, CA Schiffer et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B N Engl J Med 331 1994 896 903
90. CD Bloomfield, D Lawrence, JC Byrd et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179
91. JO Moore, SL George, RK Dodge et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 2005 3420 3427
92. F Ferrara New agents for acute myeloid leukemia: is it time for targeted therapies? Expert Opin Investig Drugs 21 2012 179 189
93. AK Burnett, RK Hills, DW Milligan et al. Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial J Clin Oncol 28 2010 586 595
94. 2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study J Clin Oncol 29 2011 2696 2702
95. PA Cassileth, DP Harrington, FR Appelbaum et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission N Engl J Med 339 1998 1649 1656
96. RA Zittoun, F Mandelli, R Willemze et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups N Engl J Med 332 1995 217 223
97. AK Burnett, K Wheatley, AH Goldstone et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial Br J Haematol 118 2002 385 400
98. TA Gooley, JW Chien, SA Pergam et al. Reduced mortality after allogeneic hematopoietic-cell transplantation N Engl J Med 363 2010 2091 2101
99. AK Burnett, RK Hills Who should be transplanted in first remission of acute myeloid leukaemia? Curr Treat Options Oncol 12 2011 329 340
100. S Brunet, M Labopin, J Esteve et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis J Clin Oncol 30 2012 735 741
101. RB Walter, TA Gooley, BL Wood et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia J Clin Oncol 29 2011 1107 1190
102. L Maurillo, F Buccisano, MI Del Principe et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia J Clin Oncol 26 2008 4944 4951
103. A Shimoni, A Nagler Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need Best Pract Res Clin Haematol 24 2011 369 379
104. M Hamadani, M Mohty, MA Kharfan-Dabaja Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia Cancer Control 18 2011 237 245
105. E Vellenga, W van Putten, GJ Ossenkoppele et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia Blood 118 2011 6037 6042
106. M Pfirrmann, G Ehninger, C Thiede et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial Lancet Oncol 13 2012 207 214
107. MA Sanz, F Lo-Coco Modern approaches to treating acute promyelocytic leukemia J Clin Oncol 29 2011 495 503
108. J Hu, YF Liu, CF Wu et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia Proc Natl Acad Sci USA 106 2009 3307 3342
109. E Estey, C Koller, AM Tsimberidou et al. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid Blood 105 2005 1307 1366
110. V Mathews, B George, E Chendamarai et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data J Clin Oncol 28 2010 3866 3871
111. HP Erba Has there been progress in the treatment of older patients with acute myeloid leukemia? Best Pract Res Clin Haematol 23 2010 495 501
112. F Ferrara Treatment of older patients with acute myeloid leukaemia Lancet 376 2010 1967 1968
113. CA Schiffer "I am older, not elderly," said the patient with acute myeloid leukemia J Clin Oncol 28 2010 521 523
114. AK Burnett, D Milligan, AG Prentice et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109 2007 1114 1124
115. F Ferrara Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge Clin Lymphoma Myeloma Leuk 11 2011 10 16
116. M Lubbert, BH Ruter, R Claus et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy Haematologica 97 2012 393 401
117. P Fenaux, GJ Mufti, E Hellstrom-Lindberg et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
118. HM Kantarjian, XG Thomas, A Dmoszynska et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia J Clin Oncol 30 2012 2670 2676
119. P Fenaux, GJ Mufti, E Hellstrom-Lindberg et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia J Clin Oncol 28 2010 562 569
120. E Estey, M de Lima, R Tibes et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 109 2007 1395 1400
121. F Ferrara, S Palmieri, G Mele Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia Haematologica 89 2004 998 1008
122. RM Stone, DT Berg, SL George et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine Blood 98 2001 548 553
123. C Gardin, P Turlure, T Fagot et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial Blood 109 2007 5129 5135
124. FR Appelbaum What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol 21 2008 667 675
125. F Ferrara, S Palmieri, M Celentano et al. Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia Leuk Lymphoma 47 2006 1593 8127
126. F Ferrara, P Musto Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly: for all, none, or which patients? Cancer 117 2011 3879 3881
127. DA Breems, WL Van Putten, PC Huijgens et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse J Clin Oncol 23 2005 1969 1978
128. EJ Feldman, U Gergis Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation? Curr Hematol Malig Rep 7 2012 74 77
129. W Plunkett, JO Liliemark, TM Adams et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy Cancer Res 47 1987 3005 3011
130. CP Leith, KJ Kopecky, J Godwin et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study Blood 89 1997 3323 3329
131. B van der Holt, B Lowenberg, AK Burnett et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis Blood 106 2005 2646 2654
132. MR Baer, SL George, RK Dodge et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood 100 2002 1224 1232
133. LD Cripe, H Uno, EM Paietta et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 Blood 116 2010 4077 4085
134. JE Kolitz, SL George, G Marcucci B Cancer and Leukemia Group P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 Blood 116 2010 1413 1421
135. PL Greenberg, SJ Lee, R Advani et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) J Clin Oncol 22 2004 1078 1086
136. BL Lum, S Kaubisch, AM Yahanda et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance J Clin Oncol 10 1992 1635 1642
137. M Norkin, JP Uberti, CA Schiffer Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leuk Res 35 2011 139 144
138. C Ustun, JS Miller, DH Munn, DJ Weisdorf, BR Blazar Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 118 2011 5084 5095
139. M Brune, S Castaigne, J Catalano et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial Blood 108 2006 88 96
140. MR Baer, SL George, MA Caligiuri et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and leukemia group B study 9720 J Clin Oncol 26 2008 4934 4939